MedTrace Logo

Oxaliplatin in Esophagus Cancer (Advanced) 1st Line

NCT00259402 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2009-12-07

No results posted yet for this study

Summary

* To determine the activity and efficacy of the schema specified as dose regimen
* To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU

Conditions

  • Esophageal Neoplasms

Interventions

DRUG

Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)

OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy

Sponsors & Collaborators

Principal Investigators

  • José Mª Taboada · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-29
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259402 on ClinicalTrials.gov